A Gene Therapy Developer that Embraces Different Models for Reaching Patients

Frederic Revah, CEO of the non-profit Genethon, discusses the limits of licensing out its discoveries to biopharma, the different development strategies it pursues, and how it determines the best path for a particular development program.